Sunitinib-induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour.
What is known and objective Sunitinib can improve progression-free survival and overall survival in patients with advanced pancreatic neuroendocrine tumor ( PNET). From clinical trial, most commonly reported adverse events of sunitinib were neutropenia (12%), diarrhea (10%), asthenia (7%), erythrody...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 38; no. 4; pp. 327 - 330 |
|---|---|
| Autores principales: | , , , , |
| Formato: | case study tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Aug2013
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104190206&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104190206 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 02694727 EV4 jtl: Journal of Clinical Pharmacy & Therapeutics issn: 02694727 maglogo: Y pubinfo: dt: Aug2013 vid: 38 iid: 4 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 104190206 88904363 10.1111/jcpt.12054 NLM23586819 104190206 ppf: 327 ppct: 3 formats: fmt: @attributes: type: P tig: atl: Sunitinib-induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour. aug: au: Shea, Y.-f. Chiu, W.-y. J. Mok, M.-y. M. Hung, I. F.-n. Yau, C.-c. T. affil: Department of Medicine, Queen Mary Hospital the University of Hong Kong sug: subj: Antineoplastic Agents Administration and Dosage Antineoplastic Agents Adverse Effects Metabolic Diseases Etiology Metabolic Diseases Diagnosis Neuroendocrine Tumors Drug Therapy Male Aged Consciousness Neoplasm Metastasis Complications Liver Neoplasms Complications Metabolic Diseases Drug Therapy Disaccharides Administration and Dosage Aged: 65+ years Male ab: What is known and objective Sunitinib can improve progression-free survival and overall survival in patients with advanced pancreatic neuroendocrine tumor ( PNET). From clinical trial, most commonly reported adverse events of sunitinib were neutropenia (12%), diarrhea (10%), asthenia (7%), erythrodysesthesia (7%), hypertension (7%) and thrombocytopenia (6%). Case summary We report a patient with PNET with liver metastases who developed hyperammonemia with a low dosage of sunitinib probably contributed by the presence of liver metastases. What is new and conclusions We would like to draw attention to the potential risk of sunitinib induced hyperammonemic encephalopathy even with a low dosage of sunitinib. The absence of sunitinib-induced hyperammonemia during its initial course does not rule out this possibility if there is increased in liver metastases. We suggest checking the ammonia level if patient on sunitinib presented with altered sensorium even if the liver function is normal. pubtype: Academic Journal doctype: case study tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|